Science Current Events | Science News | Brightsurf.com
 

Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC

April 04, 2012
CHICAGO - Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine. The findings were presented here at the AACR Annual Meeting 2012, held March 31 - April 4.

"This is a novel immunotherapy that appears to show unusually long survival in some patients," said Lyudmila Bazhenova, M.D., associate clinical professor at the University of California-San Diego Moores Cancer Center in La Jolla, Calif.

These findings represent an updated long-term survival analysis on patients treated with belagenpumatucel-L, a cell-based allogeneic vaccine derived from four lung cancer cell lines. The open-label study included 75 patients with non-small cell lung cancer (NSCLC) - two patients with stage 2 disease, 12 with stage 3A, 15 with stage 3B and 46 with stage 4. The researchers randomly assigned patients to three dose cohorts: 1.25, 2.5 or 5 Î 107 cells/injection.

For all patients, median survival was 14.5 months, and the five-year survival rate was 20 percent. The 40 patients with stage 3B/4 cancer enrolled in the second and third dose cohorts had a median survival of 15.9 months and a one-year survival rate of 61 percent, a two-year survival rate of 41 percent and a five-year survival rate of 18 percent.

Patients with stage 3B/4 nonprogressive disease after chemotherapy had a median survival of 44.4 months; five-year survival was 50 percent, which is "unheard of for patients with NSCLC," Bazhenova said.

In contrast, patients who progressed after front-line chemotherapy had a median survival rate of 14.1 months and a 9.1 percent five-year survival rate.

Bazhenova said that although these results are intriguing, they must be confirmed in a phase III clinical trial, which is currently under way in eight countries.

American Association for Cancer Research


Related Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles


TGen study identifies growth factor receptors that may prompt the spread of lung cancer
Preventing lung cancers from metastasizing to other parts of the body could provide benefit for patients against the leading cause of cancer death.

Blood test could provide rapid, accurate method of detecting solid cancers
A blood sample could one day be enough to diagnose many types of solid cancers, or to monitor the amount of cancer in a patient's body and responses to treatment.

Team identifies novel biomarker for head and neck cancer, non-small cell lung cancer
A team led by a scientist from the Florida campus of The Scripps Research Institute (TSRI) has identified a new biomarker linked to better outcomes of patients with head and neck cancers and non-small cell lung cancer.

Preoperative PET Cuts Unnecessary Lung Surgeries in Half
New quantitative data suggests that 30 percent of the surgeries performed for non-small cell lung cancer patients in a community-wide clinical study were deemed unnecessary.

Immunotherapy data heralds new era of lung cancer treatment
A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

Potential lung cancer vaccine shows renewed promise
Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer.

Using big data to identify triple-negative breast, oropharyngeal, and lung cancers
Researchers at Case Western Reserve University and colleagues used "big data" analytics to predict if a patient is suffering from aggressive triple-negative breast cancer, slower-moving cancers or non-cancerous lesions with 95 percent accuracy.

Cells appearing normal may actually be harbingers of lung cancer
Seemingly healthy cells may in fact hide clues that lung cancer will later develop, according to a study led by researchers at The University of Texas MD Anderson Cancer Center The research is published online in the Journal of the National Cancer Institute.

TGen identifies key protein that helps prevent lung cancer tumors from being destroyed
Researchers at the Translational Genomics Research Institute (TGen) have discovered a protein, Mcl-1, that helps enable one of the most common and deadly types of cancer to survive radiation and drug treatments.

Afatinib: added benefit depends on mutation status
Afatinib (trade name: GIOTRIF) has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
More Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles

Non-Small Cell Lung Cancer: Across the Continuum of Care

Non-Small Cell Lung Cancer: Across the Continuum of Care
by Asante Communications, LLC


This Clinical Resource Tool is structured around consensus statements developed by the Non-Small Cell Lung Cancer (NSCLC) Working Group, a panel of oncologists with particular expertise in the multidimensional care of patients with advanced lung cancer. Using a modified Delphi process, the NSCLC Working Group has consolidated published evidence and expert clinical experience on critical issues pertaining to the comprehensive assessment of patients with advanced NSCLC, formulation of appropriate treatment regimens, implementation of maintenance therapy, and therapeutic alliances among pathologists, oncologists, and pulmonologists. The consensus statements and accompanying resources are intended as a practical companion to current guidelines, helping clinicians individualize best-practice...

21st Century Adult Cancer Sourcebook: Non-Small Cell Lung Cancer (NSCLC) - Clinical Data for Patients, Families, and Physicians

21st Century Adult Cancer Sourcebook: Non-Small Cell Lung Cancer (NSCLC) - Clinical Data for Patients, Families, and Physicians
by Progressive Management


Authoritative information and practical advice from the nation's cancer experts about non-small cell lung cancer (NSCLC) includes official medical data on signs, symptoms, early detection, diagnostic testing, risk factors and prevention, treatment options, surgery, radiation, drugs, chemotherapy, staging, biology, prognosis, and survival, with a complete glossary of technical medical terms and current references.

Starting with the basics, and advancing to detailed patient-oriented and physician-quality information, this comprehensive in-depth compilation gives empowered patients, families, caregivers, nurses, and physicians the knowledge they need to understand the diagnosis and treatment of non-small cell lung cancer (NSCLC).

Non-small cell lung cancer is a disease...

Companion Diagnostic Testing for Non-Small Cell Lung Cancer (Oxford American Pocket Cards)

Companion Diagnostic Testing for Non-Small Cell Lung Cancer (Oxford American Pocket Cards)
by Gary H. Lyman (Author)


Lung cancer is a malignancy of epidemic proportions. In the United States, it is estimated that there will be more than 228,000 new cases of lunch cancer each year, with 40% of those presenting with Stage IV metastatic disease. Non-small cell lung cancers (NSCLC) make up approximately 70% of all lung cancers diagnosed. Ongoing advancements in medicine are raising the bar in oncology management, including NSCLCs. Data show that patients respond differently to the same drug. By identifying a sub-group of patients most likely to benefit from a specific drug therapy, patients can be confident that their treatment will provide optimal responses. A companion diagnostic enables personalized healthcare. It is used to predict which patients are most likely to benefit from a particular therapy...

Jim Cramer's Get Rich Carefully

Jim Cramer's Get Rich Carefully
by James J. Cramer (Author)


Tired of phony promises about getting rich quickly, promises that lead to reckless decisions (the stepping stones to the poor house)? How about trying something different? How about going for lasting wealth┬Śand doing it the cautious way? In Get Rich Carefully, Jim Cramer uses his thirty-five years of experience as a Wall Street veteran and host of CNBCÔÇÖs Mad Money to create a guide to high-yield, low-risk investing. In our recovering economy, this is the plan you need to make big money without taking big risks.

Drawing on his unparalleled knowledge of the stock market and on the mistakes and successes he's made on the way to his own fortune, Cramer explains┬Śin plain English┬Śwhy you can get rich in a prudent, methodical way, as long as you start now. In his own...

Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine (Pocket Notebook)

Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine (Pocket Notebook)
by Marc S. Sabatine MD (Author)


Prepared by residents and attending physicians at Massachusetts General Hospital, the 5th edition of Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine provides key clinical information and solutions to common problems faced in the practice of internal medicine.Designed to fit in a pocket, this 6-ring looseleaf binder tackles the diagnosis and treatment of the most common disorders in cardiology, pulmonary medicine, gastroenterology, nephrology, hematology-oncology, infectious diseases, endocrinology, rheumatology, and neurology.Bulleted lists combined with tables and algorithms allow busy clinicians to find the information they need rapidly. A 16-page color insert displays classic normal and abnormal radiographs, CT scans, echocardiograms, peripheral blood...

Tarascon Pocket Pharmacopoeia 2014 Deluxe Lab-Coat Edition (Tarascon Pocket Pharmacopoeia: Deluxe Lab-Coat Pocket)

Tarascon Pocket Pharmacopoeia 2014 Deluxe Lab-Coat Edition (Tarascon Pocket Pharmacopoeia: Deluxe Lab-Coat Pocket)
by MD, FAAEM, FACMT, Editor in Chief, Richard J. Hamilton (Author)


Used by prescribers around the world, including: physicians, pharmacists, nurses, physician assistants, dentists and medical transcriptionist, the Tarascon Pharmacopoeia® 2014 Deluxe Lab Coat Edition continues its tradition as the leading portable drug reference packed with vital drug information to help clinicians make better decisions at the point of care. The Tarascon Pharmacopoeia® 2014 Deluxe Lab Coat Edition is an expanded version of the Classic Shirt-Pocket Edition, containing more drugs, black box warnings, evidence-based off-label indications for adults and pediatric patients, and additional tables. This reference also includes typical drug dosing (all FDA approved), available trade and generic formulations, metabolism, safety in pregnancy and lactation, relative drug pricing...

First Aid for the USMLE Step 2 CK, Eighth Edition (First Aid USMLE)

First Aid for the USMLE Step 2 CK, Eighth Edition (First Aid USMLE)
by Tao Le (Author), Vikas Bhushan (Author)


An indispensable high-yield review for the USMLE Step 2 CK! The eighth edition of First Aid for the USMLE Step 2 CK is written by medical students who successfully passed the exam and reviewed by top faculty. The result is proven information and strategies that maximize your study time and deliver the results you want! Features:
Thousands of must-know facts that summarize frequently tested topics Completely updated based on feedback from students who passed 120+ photographs similar to those on the exam Full-color design includes numerous clinical images Rapid Review section for last-minute cramming Updated ratings of Step 2 CK review resources

Medifocus Guidebook on: Non-Small Cell Lung Cancer

Medifocus Guidebook on: Non-Small Cell Lung Cancer
by Medifocus.com (Author), Elliot Jacob PhD. (Editor)


The MediFocus Guidebook on Non-Small Cell Lung Cancer is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Non-Small Cell Lung Cancer, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Non-Small Cell Lung Cancer, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts,...

Prioritization, Delegation, and Assignment: Practice Exercises for the NCLEX Examination, 3e

Prioritization, Delegation, and Assignment: Practice Exercises for the NCLEX Examination, 3e
by Linda A. LaCharity PhD RN (Author), Candice K. Kumagai RN MSN (Author), Barbara Bartz RN MN CCRN (Author)


The only NCLEX review book on the market with a focus on prioritization, delegation, and patient assignment - just like the current NCLEX Examination itself! Using a unique simple-to-complex approach, Prioritization, Delegation, and Assignment: Practice Exercises for the NCLEX® Examination, 3rd Edition establishes your foundational knowledge in management of care, then provides exercises of increasing difficulty to help you build confidence in your prioritization, delegation, and patient assignment skills.UNIQUE! Emphasis on the NCLEX Examination's management-of-care focus addresses the heavy emphasis on prioritization, delegation, and patient assignment in the current NCLEX Examination (17-23% of the 2013 NCLEX-RN Exam).UNIQUE! Three-part organization establishes foundational knowledge...

Tarascon Pocket Pharmacopoeia 2014 Classic Shirt Pocket Edition

Tarascon Pocket Pharmacopoeia 2014 Classic Shirt Pocket Edition
by MD, FAAEM, FACMT, Editor in Chief, Richard J. Hamilton (Author)


Used by prescribers around the world, including physicians, pharmacists, nurses, physician assistants, dentists, and medical transcriptionists, the Tarascon Pocket Pharmacopoeia® 2014 Classic Shirt-Pocket Edition continues its tradition as the leading portable drug reference packed with vital drug information to help clinicians make better decisions at the point of care. The Tarascon Pocket Pharmacopoeia® 2014 Classic Shirt-Pocket Edition, now updated with over 100 new drugs, details FDA approved drug dosing, available trade and generic formulations, metabolism, safety in pregnancy and lactation, relative drug pricing information, Canadian trade names, and an herbal & alternative therapies section. Multiple tables supplement the drug content, including opioid equivalency, emergency drug...

© 2014 BrightSurf.com